摘要:
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
摘要:
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要:
The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要:
Apparatus and method for allowing a test script to be played back correctly in a locale of different test language. The invention uses a synonymy dictionary storing the different appearances of the property value of a property in an object of a software product to be tested in different test locales; and compares the property value of the property in the object of the software product to be tested to the corresponding property value pre-recorded in a test script to detect whether they match each other.
摘要:
A device comprising a substrate, an integrated circuit (IC) die attached to the substrate on one side, a plurality of contact pads on an active side of the IC die, a plurality of thermally and electrically conductive legs, each of the legs attached to a respective one of the contact pads, and an encapsulating material formed around the substrate, the IC die, and a portion of the legs. A contact end of each of the legs is exposed, and one of the contact ends conducts a signal from a transistor in the IC die.
摘要:
A method and a system are disclosed for determining application dependency paths in a data center. The method and the system captures application traffic volume data on the servers with switches and monitoring agents; generates an application traffic matrix of all the components of the applications based on the application traffic volume data; estimates the number of the applications in the data center from the traffic matrix with a Rank Estimation via Singular Value Decomposition or Power Factorization Residue Errors process; and decomposes the traffic matrix into a first matrix and a second matrix with a non-negative matrix factorization process using the estimated number of applications. The first matrix represents a set of the components belonging to each of the applications and the second matrix represents the amount of traffic generated by each application over time. Any noise in the first and second matrices is removed with a concurrent volumes ratios based correlation process.
摘要:
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
摘要:
A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
摘要:
Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.